MedTrace Logo

Effect on Beta Cell Function and Glycaemic Control After Insulin and Exenatide Sequential Therapy

NCT02129985 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2014-05-02

No results posted yet for this study

Summary

Whether GLP-1 receptor agonists sequential therapy in newly diagnosed type 2 diabetic patients can further improve glycemic control, diabetes remission rate and β-cell function after the short-term insulin intensive therapy.

Conditions

Interventions

DRUG

Exenatide

Exenatide (10 ug/bid for 3 months)

DRUG

Metformin

Metformin 850 mg/bid for 3 months

Sponsors & Collaborators

  • Shanghai Zhongshan Hospital

    collaborator OTHER

  • The third people's Hospital Affiliated to Shanghai Jiao Tong University

    collaborator UNKNOWN

  • Second Affiliated Hospital of Soochow University

    collaborator OTHER

  • The First Hospital of Guiyang Medical college

    collaborator UNKNOWN

  • Fuling Central Hospital of Chongqing City

    collaborator OTHER

  • Taizhou Hospital

    collaborator OTHER

  • Shanghai Pudong New Area Gongli Hospital

    collaborator OTHER

  • xiaolong zhao

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2015-06-30
Completion
2015-09-30

Countries

  • China

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02129985 on ClinicalTrials.gov